Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.

IF 2.6 4区医学 Q2 ONCOLOGY Future oncology Pub Date : 2025-02-01 Epub Date: 2025-01-26 DOI:10.1080/14796694.2025.2455929

Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig

{"title":"Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.","authors":"Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig","doi":"10.1080/14796694.2025.2455929","DOIUrl":null,"url":null,"abstract":"Background: The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.Research design and methods: Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.Results: N = 173 patients. No significant demographic differences in TTI or TTP. In the multivariate model TTI to death, patients with Medicaid insurance had significantly shorter overall survival than patients with private insurance.Conclusions: Medicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"565-568"},"PeriodicalIF":2.6000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845102/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Future oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14796694.2025.2455929","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.

Research design and methods: Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.

Results: N = 173 patients. No significant demographic differences in TTI or TTP. In the multivariate model TTI to death, patients with Medicaid insurance had significantly shorter overall survival than patients with private insurance.

Conclusions: Medicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

根据人口统计学变量评估CDK-4/6抑制剂治疗患者的治疗差异。

背景：根据人口统计学因素，细胞周期蛋白依赖性激酶4和6抑制剂（CDKi）在转移性乳腺癌（MBC）中的可及性和结果尚不清楚。研究设计与方法：回顾性分析2015年1月至2022年12月ER+ MBC一线CDKi治疗患者。提取包括从CDKi处方到药物起始（TTI）的时间，从CDKi起始到进展（TTP）的时间，从CDKi起始到死亡（2022年6月30日）的时间，以及变量（年龄、种族、伴侣状况、保险类型、BMI、合并症数量）。使用描述性、比较性和相关性统计。结果：N = 173例。在TTI或TTP中没有显著的人口统计学差异。在TTI至死亡的多变量模型中，医疗补助保险患者的总生存期明显短于私人保险患者。结论：医疗保险与MBC治疗的不良结果相关，而不是归因于TTI延迟。个性化的支持可能会有所帮助。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Future oncology ONCOLOGY-

CiteScore

5.40

自引率

3.00%

发文量

335

审稿时长

4-8 weeks

期刊介绍： Future Oncology (ISSN 1479-6694) provides a forum for a new era of cancer care. The journal focuses on the most important advances and highlights their relevance in the clinical setting. Furthermore, Future Oncology delivers essential information in concise, at-a-glance article formats - vital in delivering information to an increasingly time-constrained community. The journal takes a forward-looking stance toward the scientific and clinical issues, together with the economic and policy issues that confront us in this new era of cancer care. The journal includes literature awareness such as the latest developments in radiotherapy and immunotherapy, concise commentary and analysis, and full review articles all of which provide key findings, translational to the clinical setting.